Stéphane Bancel’s Post

📣 Exciting news today about mRNA-1083, Moderna’s investigational combination vaccine against influenza and COVID-19. This vaccine has the potential to ease the burden on health systems and provide more convenient vaccination options against seasonal illnesses. A huge thank you to our dedicated teams for their hard work. Together, we're advancing healthcare solutions in our mission to deliver the greatest possible impact to people through #mRNA medicines.

View organization page for Moderna, graphic

601,189 followers

We announced today that our Phase 3 trial of mRNA-1083, an investigational combination #vaccine against #influenza and #COVID19, has met its primary endpoints. mRNA-1083 comprises components of mRNA-1010, Moderna’s vaccine candidate for seasonal influenza, and mRNA-1283, Moderna’s next-generation COVID-19 vaccine candidate. Read more: https://lnkd.in/eiDqew4X

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

investors.modernatx.com

Philippe Barillon

Global Biopharma Leader | Boosting Growth with AI | Quiet extrovert

1mo

Not for me. My second Moderna « COVID » shot sent me to bed for one week with V-shape fever, headaches and muscle cramps and I developed IBD right after. Never again.

Angelica Figueiredo White

Empowering Brands with Direct Media Streaming and Engaging Consumers through Product Experiences | ZIPPYAR CEO | Revolutionizing Digital Marketing in Pharma, Retail, and CPG for Today's Generation.

1mo

We need to innovate while also makes healthcare accessible and affordable by all! Great initiative! 👏🏼👏🏼👏🏼. Having timely feedback from people taking the vaccine with their feedback can help Pharma to quickly improve the quality of vaccines and refund risks. This is something we ZIPPYAR can help pharmaceutical companies theough our safe and compliant media streaming channel with a builtin platform for patients engagement. We are looking forward to delivering value to pharmaceutical companies and while making healthcare accessible and more affordable by all people.

Like
Reply
Paul King

Passionate Account Manager | Driving Client Success at Prairie Consulting

1mo

Do these shots protect you from the illness and stop transmission?

Moazama Gul

Sr Clinical Research Coordinator/Manager

1mo

I was part of Moderna vaccine Clinical trial from flu and Covid 19. I would like to Congrats Moderna on moving forward with the project. I have seen the high Quality work Moderna did during these mRna 1083 trials. Congrats# Moderna# Great work.

Like
Reply
Siddharth Mohan

𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐀𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐞 | Analytical Chemist | Freelance Medical Writer/Editor ✦ Healthcare Management ✦ Data Analysis ✦ R & D ✦ Content Development ✦ Medical Researcher ✦ Clinical Scientist

1mo

This is incredible. I can’t wait to see the publication and how the presentations turns out

Marieke Jonkman PharmD

Medical Affairs Capabilities | Medical Affairs Executive Coaching | Leadership Development | Emotional Intelligence | Team Building | Strategic Thinking

3w

🌟 Wonderful news, Stéphane! The development of mRNA-1083 is truly exciting and represents a significant step forward in streamlining protection against major seasonal illnesses. Huge congratulations to your teams for their dedication and innovation in advancing mRNA medicines. This could indeed make a remarkable difference in public health. Keep up the fantastic work!  🦢 Shine on 🫶

Like
Reply
Judith Horn PT, DPT, MS, GCS

Doctor of Physical Therapy/Orthopedic Path; Geriatric Certified Specialist GCS; Certified Wound Specialist CWS (Ret)

1mo

I would absolutely not get a combination shot. Prefer separate shots at separate times. I have enough of a reaction to each shot on its own.

Like
Reply
Francisco J. Esteva, MD, PhD

Leading Patient-Centered Innovation in Cancer Care

1mo

Looking forward to reviewing the final results. It seems promising for next flu season.

Like
Reply
Summer Adams

Certified Senior Medical Writer, Translational and Clinical Research Consultant, Infectious Disease Epidemiologist at Adams Medical Writing and Consulting

1mo

Very exciting news. Excited to see the presentation/results. Great work.

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics